Drug Trial Radar · NCT06963827
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
347
Planned (sponsor's estimate)
Start
Jul 15, 2025
Primary completion
Sep 7, 2028
Study completion Jan 14, 2030
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- May 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find out if and how well mezagitamab continues to maintain kidney function over the long term compared to placebo. Participants will be placed in 1 of the 2 treatment groups; the main group and the open-label group. In the main group, participants will be placed by chance in either the mezagitamab or placebo treatment group at a 2:1 ratio. This means that out of 3 participants, 2 will receive mezagitamab and 1 will receive placebo. Participants can be in the study for 2 years (104 weeks). Participants will receive study treatment for about half a year (22 weeks) and then be observed for the remainder of the study (about 1.5 years). During observation, participants will continue to have check-ups about every month. In the open-label group, a small number of participants who either have lower levels of protein in their urine or have kidneys that do not filter the blood well, will receive mezagitamab treatment. This will include participants who have previously received mezagitamab in another study, TAK-079-1006. Every participant will receive mezagitamab in the same way as those in the main group receiving mezagitamab. During the study, participants will visit their study clinic several times.
Conditions
- Kidney Disease
Interventions
MezagitamabDrug
Mezagitamab injections administered SC.
PlaceboDrug
Mezagitamab-matching placebo injections administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Proteinuria at Week 36Time frame: From Baseline to Week 36
Locations
186 sites in 26 countries. Site status is shown where the registry gives one.
UAB Nephrology Research Clinic at Paula Building
Birmingham, Alabama · Recruiting
DCR Montgomery
Montgomery, Alabama · Recruiting
Panoramic Health - Southwest Kidney Institute, PLC
Surprise, Arizona · Recruiting
Panoramic Health - West Coast Kidney Institute (Fremont)
Fremont, California · Recruiting
Academic Medical Research Institute
Los Angeles, California · Recruiting
UCLA University of California Los Angeles
Los Angeles, California · Recruiting
University of California Irvine
Orange, California · Recruiting
Kaiser Permanente San Francisco Medical Center
San Francisco, California · Recruiting
Panoramic Health - Florida Kidney Physicians, LLC (Jacksonville)
Jacksonville, Florida · Recruiting
South Florida Research Institute
Lauderdale Lakes, Florida · Recruiting
Panoramic Health - Florida Kidney Physicians, LLC (Melbourne)
Melbourne, Florida · Recruiting
Bioresearch Partners
Miami, Florida · Recruiting
Total Health and Research Center (THRC)
Miami, Florida · Recruiting
CTR Oakwater, LLC
Orlando, Florida · Recruiting
Bioresearch Partners
Pembroke Pines, Florida · Recruiting
Panoramic Health - Florida Kidney Physicians, LLC (Tampa)
Riverview, Florida · Recruiting
Infigo Clinical Research LLC
Sanford, Florida · Recruiting
DCR Columbus
Columbus, Georgia · Recruiting
Panoramic Health - Southeast Kidney Associates
East Point, Georgia · Recruiting
CARE Institute - Boise Kidney
Boise, Idaho · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Panoramic Health - RNA of Rockford, LLC dba Rockford Nephrology Associates
Rockford, Illinois · Recruiting
Northwest Louisiana Nephrology
Shreveport, Louisiana · Recruiting
Ingham Nephrology & Hypertension, P.C.
Lansing, Michigan · Recruiting
Elixia MKC
Pontiac, Michigan · Recruiting
Panoramic Health - Lake Michigan Nephrology, PLC
Saint Joseph, Michigan · Recruiting
DCR Edina
Edina, Minnesota · Recruiting
Elixia MNA
City of Saint Peters, Missouri · Recruiting
Clinical Research Consultants a JCCT Company
Kansas City, Missouri · Recruiting
Renal Medicine Associates - Frenova F1
Albuquerque, New Mexico · Recruiting
Brookview Hills Research Associates, LLC
Winston-Salem, North Carolina · Recruiting
Panoramic Health - Kidney and Hypertension Center
Cincinnati, Ohio · Recruiting
Panoramic Health - Clinical Renal Associates, Ltd.
Media, Pennsylvania · Recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
Panoramic Health - Nephrology Associates, Inc.
East Providence, Rhode Island · Recruiting
Dallas Renal Group
Dallas, Texas · Recruiting
DCR - El Paso
El Paso, Texas · Recruiting
Houston Methodist Research Institute - Department of Medicine
Houston, Texas · Recruiting
Provecta Research Network
Houston, Texas · Recruiting
Nephrology Associates of Houston PLLC
Katy, Texas · Recruiting
Showing 40 of 186 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.